

# Folinic acid (Calcium)

## **Catalog No: tcsc1363**

Available Sizes

**Size:** 100mg

Size: 500mg

Specifications

CAS No:

1492-18-8

## Formula:

 $\mathsf{C}_{20}\mathsf{H}_{21}\mathsf{CaN}_7\mathsf{O}_7$ 

Pathway: Cell Cycle/DNA Damage

### **Target:**

Antifolate

Purity / Grade:

>98%

## **Solubility:** H2O : ≥ 200 mg/mL (391.01 mM)

#### **Alternative Names:**

Leucovorin Calcium; Calcium Folinate

# **Observed Molecular Weight:**

511.5

## **Product Description**

Leucovorin Calcium is a reduced folic acid.

Copyright 2021 Taiclone Biotech Corp.




IC50 Value: 30  $\mu$ M for zcSHMT and70  $\mu$ M for zmSHMT [2]

#### Target: Antifolate

in vitro: Increasing concentrations of leucovorin (N5-CHO-THF) inhibit both zcSHMT and hcSHMT activities substantially, yet to a lesser extent than zmSHMT. The IC50 of leucovorin is approximately 30  $\mu$ M for zcSHMT and higher than 70  $\mu$ M for zmSHMT. The differential inhibition is evident with the presence of 10  $\mu$ M leucovorin, the concentration estimated in serum in a high-dose leucovorin rescue regimen [2].

in vivo: Following intravenous administration, peak plasma concentrations of (6R) LV, (6S) LV, and 5-CH3 THF were 148 +/- 32, 59.1 +/- 22, and 17.8 +/- 17 microM, respectively. During oral administration of LV, virtually no (6S) LV appeared in the plasma. Steadystate plasma concentrations of (6R) LV and 5-CH3 THF were approximately 1.5 +/- 0.23 and 2.8 +/- 0.41 microM, respectively [1]. 24 fasted subjects were given 4 of a series of 5 single test doses between 20 and 100 mg, at 1-week intervals, of 5-formyl-THF as an oral solution of leucovorin calcium. Six separate subjects received 200 mg iv and po in a 2-way crossover. Blood and urine samples were collected over 24 hours for differential microbiological folate assays using Lactobacillus casei and Streptococcus faecalis. Using L casei activity to measure total serum folates, the area under the concentration-time curve from 0 to infinite time (AUC[0-infinity]) was calculated. Relative bioavailabilities were 78%, 62%, 49%, and 42% for the 40-, 60-, 80-, and 100-mg doses, respectively [3].

Clinical trial: Leucovorin and Fluorouracil With or Without SU-5416 in Treating Patients With Metastatic Colorectal Cancer . Phase 3



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.